NewAmsterdam Pharma (NAMS) Institutional Ownership

During the previous two years, 127 institutional investors and hedge funds held shares of NewAmsterdam Pharma. The most heavily invested institutionals were Frazier Life Sciences Management L.P. ($300.75M), Bain Capital Life Sciences Investors LLC ($275.48M), Fcpm Iii Services B.V. ($272.35M), RA Capital Management L.P. ($207.54M), Deerfield Management Company L.P. Series C ($110.88M), Wellington Management Group LLP ($72.50M), and Adage Capital Partners GP L.L.C. ($54.57M).Learn more on NewAmsterdam Pharma's institutional investors.

89.89% of NewAmsterdam Pharma's stock is owned by institutional investors. Learn more on NAMS's institutional investor holdings.

Of the 112 institutional investors that purchased NewAmsterdam Pharma's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Fcpm Iii Services B.V. ($11.83M), Wellington Management Group LLP ($5.68M), Frazier Life Sciences Management L.P. ($4.38M), Jennison Associates LLC ($3.99M), Deerfield Management Company L.P. Series C ($3.61M), Alliancebernstein L.P. ($2.33M), and RA Capital Management L.P. ($2.07M).

Institutional investors have bought a total of 38,550,376 shares in the last 24 months. This purchase volume represents approximately $907.42M in transactions.

Of the 37 institutional investors that sold NewAmsterdam Pharma's stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Fcpm Iii Services B.V. ($1.23M), Jennison Associates LLC ($1.05M), GMT Capital Corp ($543.90K), Adage Capital Partners GP L.L.C. ($330K), Alyeska Investment Group L.P. ($193.45K), Siren L.L.C. ($183.61K), and Bank of America Corp DE ($175.30K).

Institutional investors have sold a total of 4,859,942 shares in the last 24 months. This volume of shares sold represents approximately $111.43M in transactions.